LU91606I2 - pioglitazone en association avec du glimépiride etses dérivés pharmaceutiquement acceptables -TANDE MACT - Google Patents

pioglitazone en association avec du glimépiride etses dérivés pharmaceutiquement acceptables -TANDE MACT

Info

Publication number
LU91606I2
LU91606I2 LU91606C LU91606C LU91606I2 LU 91606 I2 LU91606 I2 LU 91606I2 LU 91606 C LU91606 C LU 91606C LU 91606 C LU91606 C LU 91606C LU 91606 I2 LU91606 I2 LU 91606I2
Authority
LU
Luxembourg
Prior art keywords
glimepiride
pioglitazone
combination
pharmaceutically acceptable
acceptable derivatives
Prior art date
Application number
LU91606C
Other languages
English (en)
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15563926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91606(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of LU91606I2 publication Critical patent/LU91606I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
LU91606C 1995-06-20 2009-09-09 pioglitazone en association avec du glimépiride etses dérivés pharmaceutiquement acceptables -TANDE MACT LU91606I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP15350095 1995-06-20
EP98200252A EP0861666B1 (fr) 1995-06-20 1996-06-20 Composition pharmaceutique pour utilisation dans le traitement du diabète
EP96304570A EP0749751A3 (fr) 1995-06-20 1996-06-20 Composition pharmaceutique pour utilisation dans le traitement du diabète

Publications (1)

Publication Number Publication Date
LU91606I2 true LU91606I2 (fr) 2009-11-09

Family

ID=15563926

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91298C LU91298I2 (fr) 1995-06-20 2006-12-20 Pioglitazone en association avec la metformine et ses dérivés pharmaceutiquement acceptables-competact
LU91606C LU91606I2 (fr) 1995-06-20 2009-09-09 pioglitazone en association avec du glimépiride etses dérivés pharmaceutiquement acceptables -TANDE MACT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU91298C LU91298I2 (fr) 1995-06-20 2006-12-20 Pioglitazone en association avec la metformine et ses dérivés pharmaceutiquement acceptables-competact

Country Status (26)

Country Link
US (44) US5952356A (fr)
EP (6) EP2292268A1 (fr)
JP (3) JP3148973B2 (fr)
KR (3) KR970000233A (fr)
CN (3) CN1289082C (fr)
AR (4) AR005641A1 (fr)
AT (2) ATE256463T1 (fr)
CA (3) CA2533845C (fr)
CY (4) CY2424B1 (fr)
CZ (2) CZ291624B6 (fr)
DE (4) DE122009000064I1 (fr)
DK (2) DK1174135T3 (fr)
ES (2) ES2212208T3 (fr)
FR (1) FR09C0055I2 (fr)
HK (2) HK1010484A1 (fr)
HU (1) HUP9601698A3 (fr)
LU (2) LU91298I2 (fr)
MX (1) MX9602399A (fr)
MY (1) MY127530A (fr)
NL (2) NL300258I2 (fr)
NO (5) NO313226B1 (fr)
PT (2) PT861666E (fr)
RU (5) RU2327455C2 (fr)
SK (2) SK287351B6 (fr)
TW (2) TWI238064B (fr)
ZA (1) ZA965190B (fr)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
EP0851757A2 (fr) 1995-08-10 1998-07-08 Warner-Lambert Company Procede permettant de reduire la quantite d'insuline exogene administree a un patient souffrant de diabete sucre non-insulinodependant
DE69713890T3 (de) * 1996-04-05 2006-09-07 Takeda Pharmaceutical Co. Ltd. Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
DE69734405T2 (de) 1996-07-15 2006-08-03 Sankyo Co., Ltd. Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
TR199903072T2 (xx) * 1997-06-18 2000-07-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve alfa-glukosidaz ile tedavisi.
IL133142A0 (en) * 1997-06-18 2001-03-19 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
AU778947B2 (en) * 1997-06-18 2004-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
NZ501163A (en) * 1997-06-18 2002-02-01 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and sulphonylurea (glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide
AU783539B2 (en) * 1997-06-18 2005-11-10 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AU782419B2 (en) * 1997-07-18 2005-07-28 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
PL191533B1 (pl) * 1997-10-20 2006-06-30 Dainippon Sumitomo Pharma Co Szybko-rozpuszczalna kompozycja farmaceutyczna
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE69939864D1 (de) 1998-01-29 2008-12-18 Amgen Inc Ppar-gamma modulatoren
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
ID27415A (id) * 1998-06-30 2001-04-05 Takeda Chemical Industries Ltd Komposisi farmaseutik
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
ES2206868T3 (es) * 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US7528133B1 (en) 1998-10-29 2009-05-05 The Board Of Regents Of The University Of Texas System Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
HUP0104303A3 (en) * 1998-11-12 2003-12-29 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
AP1692A (en) * 1998-11-12 2006-12-12 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
US6958324B2 (en) 1998-12-02 2005-10-25 Inotek Pharmaceuticals Corporation Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU771039B2 (en) * 1998-12-24 2004-03-11 Metabasis Therapeutics, Inc. A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
EP1147879B8 (fr) * 1999-01-29 2008-12-24 Takeda Pharmaceutical Company Limited Maillet de compression avec revètement
JP4799720B2 (ja) * 1999-01-29 2011-10-26 武田薬品工業株式会社 コーティング処理を施した打錠用杵
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
ATE384035T1 (de) * 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
JP2000355550A (ja) * 1999-04-14 2000-12-26 Takeda Chem Ind Ltd ケトーシス改善剤
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
TR200103061T2 (tr) * 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
GB9910693D0 (en) * 1999-05-07 1999-07-07 Univ Liverpool A compound for use in medicine
US6214842B1 (en) * 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
US6380191B1 (en) * 1999-06-18 2002-04-30 Merck & Co. Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
JP2003503356A (ja) * 1999-06-25 2003-01-28 メドトロニック ミニメド インコーポレイテッド 多剤糖尿病治療
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU779730B2 (en) * 1999-06-30 2005-02-10 Amgen, Inc. Compounds for the modulation of PPARgamma activity
JP4295458B2 (ja) * 1999-06-30 2009-07-15 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ活性調節用化合物
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN1287779C (zh) * 1999-10-06 2006-12-06 黑川清 羰基压迫降低剂
WO2001026639A2 (fr) * 1999-10-08 2001-04-19 Novartis Ag Procede de traitement de troubles du metabolisme
US6274622B1 (en) * 1999-10-27 2001-08-14 Frederick H. Hausheer Method of treating diabetic ophthalmopathy
BR0015294A (pt) 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US6660021B1 (en) 1999-12-23 2003-12-09 Advanced Cardiovascular Systems, Inc. Intravascular device and system
US6575997B1 (en) 1999-12-23 2003-06-10 Endovascular Technologies, Inc. Embolic basket
US6402771B1 (en) 1999-12-23 2002-06-11 Guidant Endovascular Solutions Snare
WO2001047509A2 (fr) * 1999-12-24 2001-07-05 Smithkline Beecham P.L.C. Procede de traitement
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
US6695813B1 (en) 1999-12-30 2004-02-24 Advanced Cardiovascular Systems, Inc. Embolic protection devices
US7918820B2 (en) 1999-12-30 2011-04-05 Advanced Cardiovascular Systems, Inc. Device for, and method of, blocking emboli in vessels such as blood arteries
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
AU2001229601A1 (en) * 2000-01-24 2001-07-31 Inotek Corporation Method and composition for modulating an immune response
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
WO2001058491A1 (fr) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Medicament comprenant une combinaison
CA2401356A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicament combine
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
US6461639B2 (en) 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
WO2001082916A2 (fr) 2000-05-03 2001-11-08 Tularik Inc. Compositions therapeutiques combinees et leurs methodes d'utilisation
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6939362B2 (en) * 2001-11-27 2005-09-06 Advanced Cardiovascular Systems, Inc. Offset proximal cage for embolic filtering devices
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6964670B1 (en) 2000-07-13 2005-11-15 Advanced Cardiovascular Systems, Inc. Embolic protection guide wire
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
ZA200302507B (en) * 2000-10-12 2004-03-31 Nisaan Chemical Ind Ltd Preventives and remedies for complications of diabetes.
US6506203B1 (en) 2000-12-19 2003-01-14 Advanced Cardiovascular Systems, Inc. Low profile sheathless embolic protection system
PL362687A1 (en) 2001-01-12 2004-11-02 Sun Pharmaceutical Industries Limited Spaced drug delivery system
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
EP1236720B1 (fr) 2001-02-28 2005-06-15 Pfizer Products Inc. Derives de sulfonyl-pyridazinone comme inhibiteurs de reductase d'aldose
ES2266494T3 (es) * 2001-03-02 2007-03-01 Divapharma Chur Ag Formulacion combinado para el tratamiento de la de la diabetes mellitas.
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
CN1215067C (zh) 2001-03-30 2005-08-17 辉瑞产品公司 哒嗪酮醛糖还原酶抑制剂
JPWO2002080924A1 (ja) * 2001-04-03 2004-07-29 山之内製薬株式会社 アリールエテンスルホンアミド誘導体の新規な用途
ES2373873T3 (es) * 2001-04-10 2012-02-09 Sun Pharma Advanced Research Company Limited Composición de liberación por impulso temporizado.
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US6599307B1 (en) 2001-06-29 2003-07-29 Advanced Cardiovascular Systems, Inc. Filter device for embolic protection systems
US7338510B2 (en) 2001-06-29 2008-03-04 Advanced Cardiovascular Systems, Inc. Variable thickness embolic filtering devices and method of manufacturing the same
JP2004536843A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド ピオグリタゾンおよびビグアナイドを含むコア製剤
AU2001273310B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. A core formulation
US6638294B1 (en) 2001-08-30 2003-10-28 Advanced Cardiovascular Systems, Inc. Self furling umbrella frame for carotid filter
US6592606B2 (en) 2001-08-31 2003-07-15 Advanced Cardiovascular Systems, Inc. Hinged short cage for an embolic protection device
US8262689B2 (en) 2001-09-28 2012-09-11 Advanced Cardiovascular Systems, Inc. Embolic filtering devices
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7241304B2 (en) 2001-12-21 2007-07-10 Advanced Cardiovascular Systems, Inc. Flexible and conformable embolic filtering devices
DE10200138A1 (de) * 2002-01-04 2003-07-17 Karl Winkler Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors
TWI327462B (en) * 2002-01-18 2010-07-21 Sumitomo Chemical Co Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
TW200305415A (en) * 2002-03-22 2003-11-01 Novartis Ag Combination of organic compounds
WO2003091728A1 (fr) * 2002-04-26 2003-11-06 Takeda Chemical Industries, Ltd. Methode de criblage
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2003105809A1 (fr) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
WO2004012715A1 (fr) 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Preparations a liberation soutenue de metformine
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR101363679B1 (ko) 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7252675B2 (en) 2002-09-30 2007-08-07 Advanced Cardiovascular, Inc. Embolic filtering devices
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040088000A1 (en) 2002-10-31 2004-05-06 Muller Paul F. Single-wire expandable cages for embolic filtering devices
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
IN192749B (fr) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
CA2514539C (fr) * 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Procede pour realiser une preparation enrobee
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US8591540B2 (en) 2003-02-27 2013-11-26 Abbott Cardiovascular Systems Inc. Embolic filtering devices
WO2004108067A2 (fr) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Systeme de distribution de medicaments programme
MXPA05010945A (es) * 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
US7820158B2 (en) * 2003-04-10 2010-10-26 Surmodics, Inc. Ligand-coupled initiator polymers and methods of use
US7772272B2 (en) * 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
WO2004096278A1 (fr) * 2003-04-28 2004-11-11 Sankyo Company, Limited Activateur de la production d'adiponectine
WO2004101560A1 (fr) * 2003-05-13 2004-11-25 Synthon B.V. Procedes de fabrication de derives de thiazolidinedione et composes associes
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
AU2004250994B2 (en) * 2003-06-27 2010-12-02 Dr. Reddy's Research Foundation Compositions comprising balaglitazone and further antidiabetic compounds
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP2007508241A (ja) * 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Ｐｄｅ１０ａ阻害剤を用いる糖尿病および関連障害の処置方法
EP1510208A1 (fr) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
AU2004282999A1 (en) * 2003-10-27 2005-05-06 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
WO2005041962A1 (fr) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan
US7892251B1 (en) 2003-11-12 2011-02-22 Advanced Cardiovascular Systems, Inc. Component for delivering and locking a medical device to a guide wire
EP1732513A2 (fr) * 2003-12-31 2006-12-20 Alpharma, Inc. Preparations de rosiglitazone
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
US7360069B2 (en) * 2004-01-13 2008-04-15 Hewlett-Packard Development Company, L.P. Systems and methods for executing across at least one memory barrier employing speculative fills
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
WO2005080387A2 (fr) * 2004-02-20 2005-09-01 Synthon B.V. Procedes pour produire de la pioglitazone et composes issus de ces procedes
JP2007526309A (ja) * 2004-03-02 2007-09-13 アベール ファーマシューティカルズ インコーポレイテッド 生物活性剤の混合製剤またはキット
US7678129B1 (en) 2004-03-19 2010-03-16 Advanced Cardiovascular Systems, Inc. Locking component for an embolic filter assembly
US7161756B2 (en) * 2004-05-10 2007-01-09 Tandberg Data Storage Asa Method and system for communication between a tape drive and an external device
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
EP1773376A4 (fr) * 2004-08-03 2009-07-01 Emisphere Tech Inc Association d'insuline et d'un biguanide pour administration orale contre le diabète
WO2006032011A2 (fr) * 2004-09-14 2006-03-23 Elixir Pharmaceuticals, Inc. Therapie combinee destinee a la digestion controlee d'hydrates de carbone
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US9259305B2 (en) 2005-03-31 2016-02-16 Abbott Cardiovascular Systems Inc. Guide wire locking mechanism for rapid exchange and other catheter systems
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
EP1898931B1 (fr) * 2005-07-07 2014-12-31 Postech Foundation Modulateur de captage du glucose et procede de traitement du diabete et des complications du diabete
CA2614664A1 (fr) * 2005-07-14 2007-01-25 Franco Folli Schema posologique quotidien pour le traitement du diabete, de l'obesite, du syndrome metabolique et du syndrome des ovaires polykystiques
BRPI0613670A2 (pt) * 2005-07-22 2011-01-25 Procter & Gamble composições para redução da incidência de arritmia induzida por fármacos
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
ES2576258T3 (es) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007105730A1 (fr) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. Agent ameliorant l'insulinoresistance
JP5269758B2 (ja) 2006-03-16 2013-08-21 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体
AU2007235145B2 (en) * 2006-03-31 2011-09-22 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
US7727404B2 (en) * 2006-04-11 2010-06-01 Sorbwater Technology As Method for removal of materials from a liquid stream
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
US7752724B2 (en) * 2006-06-27 2010-07-13 Lumino, Inc. Method of cutting blinds
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
WO2008091624A2 (fr) * 2007-01-22 2008-07-31 Teva Pharmaceutical Industries Ltd. Formes polymorphes de bromhydrate de rosiglitazone et leurs procédés de préparation
EP2106260B8 (fr) 2007-01-25 2018-04-04 Naia Metabolic, Inc. Sensibilisateurs a l'iinsuline et procédés de traitement
CA2677201C (fr) * 2007-02-01 2015-11-17 Takeda Pharmaceutical Company Limited Preparation solide comprenant de alogliptine et de la pioglitazone
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
NZ580963A (en) 2007-04-11 2012-08-31 Omeros Corp Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8216209B2 (en) 2007-05-31 2012-07-10 Abbott Cardiovascular Systems Inc. Method and apparatus for delivering an agent to a kidney
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US7867273B2 (en) 2007-06-27 2011-01-11 Abbott Laboratories Endoprostheses for peripheral arteries and other body vessels
CA2694590A1 (fr) 2007-07-26 2009-01-29 Amgen Inc. Enzymes de lecithine cholesterol acyltransferase modifiees
NZ583889A (en) * 2007-09-14 2012-01-12 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension
JPWO2009038107A1 (ja) * 2007-09-21 2011-01-06 キッセイ薬品工業株式会社 ２型糖尿病治療用の組合せ医薬
WO2009073627A1 (fr) * 2007-11-30 2009-06-11 The Research Foundation Of State University Of New York Biomarqueur de remplacement de combustible métabolique
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (fr) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques comprenant un sensibilisateur à l insuline et un secrétagogue d insuline
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2735578C (fr) * 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Methode de determination de facteurs de risque de la maladie d'alzheimer comprenant des variants du gene tomm40
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102348457A (zh) 2009-03-11 2012-02-08 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20110038848A1 (en) * 2009-08-12 2011-02-17 Melaleuca, Inc. Dietary supplement compositions for cardiovascular health
EP2500020B1 (fr) 2009-11-13 2014-09-10 Toray Industries, Inc. Agent de traitement ou de prévention du diabète
ES2629170T3 (es) * 2009-12-04 2017-08-07 Senhwa Biosciences, Inc. Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2
KR20120103711A (ko) * 2009-12-15 2012-09-19 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 신경퇴행성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
ES2658168T3 (es) * 2009-12-15 2018-03-08 Cirius Therapeutics, Inc. Sales de tiazolidinadiona ahorradoras de PPAR para el tratamiento de enfermedades metabólicas
JP2013523681A (ja) 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
WO2011127051A1 (fr) * 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur de gpr119 et traitement de troubles associés
RU2526153C2 (ru) * 2010-07-15 2014-08-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
EP2611434A1 (fr) 2010-09-01 2013-07-10 Lupin Limited Composition pharmaceutique contenant de la metformine et de la pioglitazone
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN103501783A (zh) 2011-01-10 2014-01-08 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
RU2017124629A (ru) 2011-01-20 2019-01-30 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
WO2013034174A1 (fr) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Préparations solides de pioglitazone et de glimépiride
ES2633766T3 (es) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico
CA2858572C (fr) 2011-12-08 2023-01-17 Amgen Inc. Proteines liant un antigene lcat humain et leur utilisation en therapie
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
CA2913737A1 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procede de production et d'utilisation
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
RU2572706C1 (ru) * 2014-06-30 2016-01-20 Олег Ильич Эпштейн Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
EP3253382B1 (fr) 2015-02-06 2021-11-17 Intercept Pharmaceuticals, Inc. Compositions pharmaceutiques pour thérapie combinée
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
EP3568134A1 (fr) 2017-01-16 2019-11-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Procédés et compositions pharmaceutiques pour réduire la motilité cellulaire médiée par cd95
JP2021528738A (ja) 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ メトホルミン医薬組成物を用いて血糖を低下させるための方法
JP2022536060A (ja) 2019-05-30 2022-08-12 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物
CN112869173A (zh) * 2021-01-18 2021-06-01 广州富诺营养科技有限公司 一种复合维生素矿物质制剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5728073A (en) * 1980-07-29 1982-02-15 Takeda Chem Ind Ltd Inhibitor for aldose reducing enzyme
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
AU598366B2 (en) 1987-03-20 1990-06-21 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
JPH0466579A (ja) * 1990-07-04 1992-03-02 Yamanouchi Pharmaceut Co Ltd チアゾリジン誘導体
JPH0469383A (ja) * 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd 置換チアゾリジン誘導体
US5260275A (en) 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
CA2052014A1 (fr) * 1990-10-19 1992-04-20 Henry Y. Pan Methode de prevention des complications du diabete faisant appel a un hypocholesterolemiant seul ou en association avec un inhibiteur de l'enzyme de conversion de l'angiotensine
JP2686861B2 (ja) * 1991-03-30 1997-12-08 キッセイ薬品工業株式会社 新規なベンジリデンコハク酸誘導体
DE69219136T2 (de) * 1991-08-26 1997-08-28 Upjohn Co Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH07316144A (ja) * 1994-03-29 1995-12-05 Sankyo Co Ltd ジフェニルメチルピペラジン誘導体
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715298D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6001049A (en) * 1998-02-12 1999-12-14 Frey; Mark P. Light weight exercise apparatus

Also Published As

Publication number Publication date
US20020042434A1 (en) 2002-04-11
US6172089B1 (en) 2001-01-09
SK287351B6 (sk) 2010-08-09
CY2007001I2 (el) 2009-11-04
JP3973280B2 (ja) 2007-09-12
NO317341B1 (no) 2004-10-11
CA2533845C (fr) 2012-10-09
DE122007000002I1 (de) 2012-03-08
TWI238064B (en) 2005-08-21
US6080765A (en) 2000-06-27
JPH0967271A (ja) 1997-03-11
US6211205B1 (en) 2001-04-03
DE69637988D1 (de) 2009-09-17
US6277869B1 (en) 2001-08-21
KR970000233A (ko) 1997-01-21
EP1174135B2 (fr) 2016-09-14
CY2009018I2 (el) 2010-07-28
EP1174135A3 (fr) 2002-06-19
CA2531834A1 (fr) 1996-12-21
US6156773A (en) 2000-12-05
CA2533845A1 (fr) 1996-12-21
NO20021172D0 (no) 2002-03-08
CN1530106A (zh) 2004-09-22
EP2289556A2 (fr) 2011-03-02
NO314065B1 (no) 2003-01-27
FR09C0055I1 (fr) 2009-04-12
US6169099B1 (en) 2001-01-02
US20030216443A1 (en) 2003-11-20
CY2608B2 (en) 2010-04-28
KR20080005162A (ko) 2008-01-10
RU2286148C2 (ru) 2006-10-27
CZ181196A3 (en) 1997-01-15
AU5603496A (en) 1997-01-09
US6133295A (en) 2000-10-17
CZ291624B6 (cs) 2003-04-16
US20020123512A1 (en) 2002-09-05
NO962606L (no) 1996-12-23
DE69631157D1 (de) 2004-01-29
NL300432I1 (en) 2010-03-01
EP1174135B9 (fr) 2009-12-16
CY2424B1 (en) 2004-11-12
US20070203198A1 (en) 2007-08-30
US7842706B2 (en) 2010-11-30
JP4809806B2 (ja) 2011-11-09
EP0749751A2 (fr) 1996-12-27
DE122009000064I1 (de) 2011-12-01
EP1174135B1 (fr) 2009-08-05
DE122007000002I2 (de) 2012-03-08
US5952356A (en) 1999-09-14
RU2198682C2 (ru) 2003-02-20
NO20004345L (no) 1996-12-23
US6211206B1 (en) 2001-04-03
EP2289556A3 (fr) 2011-03-09
CN1212117C (zh) 2005-07-27
ATE438397T1 (de) 2009-08-15
NL300258I2 (nl) 2007-05-01
NO2007007I2 (no) 2009-10-05
DE69631157T2 (de) 2004-09-09
CN1530105A (zh) 2004-09-22
US20050054685A1 (en) 2005-03-10
ES2212208T3 (es) 2004-07-16
US20020128289A1 (en) 2002-09-12
HK1010484A1 (en) 1999-06-25
ZA965190B (en) 1997-12-19
US6239153B1 (en) 2001-05-29
RU2323004C2 (ru) 2008-04-27
US6166042A (en) 2000-12-26
US6172090B1 (en) 2001-01-09
US6384062B1 (en) 2002-05-07
RU2327455C2 (ru) 2008-06-27
US6169100B1 (en) 2001-01-02
HUP9601698A3 (en) 2000-09-28
KR20070081135A (ko) 2007-08-16
NL300432I2 (en) 2010-04-01
US20020002186A1 (en) 2002-01-03
EP0861666A3 (fr) 1999-02-10
HK1041203B (zh) 2009-09-25
NL300258I1 (nl) 2007-04-02
CY2007001I1 (el) 2009-11-04
EP1174135A2 (fr) 2002-01-23
US6211207B1 (en) 2001-04-03
NO2007007I1 (no) 2007-06-18
US6323225B1 (en) 2001-11-27
US6166043A (en) 2000-12-26
US6133293A (en) 2000-10-17
RU2003130978A (ru) 2005-04-20
US6599923B2 (en) 2003-07-29
SK79496A3 (en) 1997-01-08
US7144900B2 (en) 2006-12-05
NO2007001I2 (no) 2011-03-14
CA2179584C (fr) 2007-04-24
JP2007191494A (ja) 2007-08-02
EP2292268A1 (fr) 2011-03-09
EP0749751A3 (fr) 1997-04-16
US6274605B1 (en) 2001-08-14
HU9601698D0 (en) 1996-08-28
EP0861666B1 (fr) 2003-12-17
LU91298I2 (fr) 2007-02-20
EP1764110A1 (fr) 2007-03-21
US6303640B1 (en) 2001-10-16
AR065389A2 (es) 2009-06-03
CA2531834C (fr) 2006-12-05
AR005641A1 (es) 1999-07-14
CN1289082C (zh) 2006-12-13
AR091289A2 (es) 2015-01-28
US20110034518A1 (en) 2011-02-10
ES2327383T5 (es) 2017-03-13
US6329404B1 (en) 2001-12-11
TW438587B (en) 2001-06-07
CA2179584A1 (fr) 1996-12-21
US5965584A (en) 1999-10-12
MX9602399A (es) 1997-02-28
US6251924B1 (en) 2001-06-26
FR09C0055I2 (fr) 2010-06-11
HK1041203A1 (en) 2002-07-05
NO962606D0 (no) 1996-06-19
CY2009018I1 (el) 2010-07-28
US6121295A (en) 2000-09-19
ATE256463T1 (de) 2004-01-15
MY127530A (en) 2006-12-29
US20090246232A1 (en) 2009-10-01
DK0861666T3 (da) 2004-03-08
NO2007001I1 (no) 2007-01-29
US6288090B1 (en) 2001-09-11
ES2327383T3 (es) 2009-10-29
US6232330B1 (en) 2001-05-15
US6214848B1 (en) 2001-04-10
US6150383A (en) 2000-11-21
SK287287B6 (sk) 2010-05-07
HUP9601698A2 (hu) 1997-05-28
AR061195A2 (es) 2008-08-13
US6121294A (en) 2000-09-19
EP0861666A2 (fr) 1998-09-02
US7538125B2 (en) 2009-05-26
US6271243B1 (en) 2001-08-07
US6174904B1 (en) 2001-01-16
AU723097B2 (en) 2000-08-17
NO313226B1 (no) 2002-09-02
CZ292093B6 (cs) 2003-07-16
PT861666E (pt) 2004-05-31
US6225326B1 (en) 2001-05-01
CN1145783A (zh) 1997-03-26
JPH10167986A (ja) 1998-06-23
RU2223760C2 (ru) 2004-02-20
US6911459B2 (en) 2005-06-28
PT1174135E (pt) 2009-08-31
DK1174135T3 (da) 2009-12-07
US20040266830A1 (en) 2004-12-30
NO20004345D0 (no) 2000-09-01
US6218409B1 (en) 2001-04-17
US6150384A (en) 2000-11-21
JP3148973B2 (ja) 2001-03-26
NO20021172L (no) 1996-12-23
US6103742A (en) 2000-08-15

Similar Documents

Publication Publication Date Title
LU91606I2 (fr) pioglitazone en association avec du glimépiride etses dérivés pharmaceutiquement acceptables -TANDE MACT
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
HU9601475D0 (en) Substituted n-(indolo-2-carbonyl)-glycinamides and derivatives as antidiabetic agents
PL314603A1 (en) Substituted n-(indolo-2-carbonyl)-beta-alaninamides and their derivatives as antidiabetic agents
GB9515775D0 (en) Piperidine derivatives and their use as therapeutic agents
NZ321576A (en) 6-imidazol-1-ylmethyl-2-oxo-quinoline derivatives and medicaments
SG91796A1 (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use
KR970702861A (ko) 포르포시아닌 및 cnc-확장된 포르피린(porphocyanine and cnc-expanded porphyrins)
GR3035663T3 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
NZ308471A (en) 1,2,3,4 tetrahydro-2-naphthalenamine with a phenyl substituent in position 5, their use and derivatives
IL128902A0 (en) N-(2-benzothiazolyl)-1-piperidineethanamine derivatives their preparation and their use in therapy
DK0761145T3 (da) Forbedringer ved og i forbindelse med soveposer
HUP9802736A3 (en) Use of 1,4-dihydropyridine derivatives for the preparation of medicament for the prevention and therapy of atherosclerotic degradation in the arterial walls
DE9400389U1 (de) Fahrrad-Rückspiegel
GB9621419D0 (en) 3-3-disubstituted piperidine derivatives and their use as therapeutic agents
GB2312834B (en) Anti-rebound bar and footrest
FR2742119B1 (fr) Embarcation en au moins deux parties montables et demontables
FR2725957B1 (fr) Sac inviolable et refermable perfectionne
ZA954025B (en) Metabolite and derivatives
DE29520157U1 (de) Sitz- und Spielobjekt
KR960007542U (ko) 리어 시트
NO975487D0 (no) 2-azabicyklo£2,2,1|heptanderivater, deres fremstilling og anvendelse
KR960009865U (ko) 전후좌우 연결식 깔판
ITRM950788A0 (it) Lettino pieghevole e chiudibile